Article: article from journal or magazin.
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Rhumatologie. Une nouvelle option thérapeutique dans la prise en charge de l'inflammation chronique en rhumatologie: les inhibiteurs des janus kinases [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Revue Médicale Suisse
Publication types: English Abstract ; Journal Article Publication Status: ppublish
In the last 15 years, the therapeutical options for the treatment of chronic inflammatory diseases in rheumatology have increased a lot. Nevertheless, some patients do not respond or respond partially to the current therapies--including to the biologics therapy. Tofacitinib (Xeljanz) is now on the Swiss market. It inhibits the JAK pathway. Tofacitinib--as monotherapy or with methotrexate--improves the control of rheumatoid arthritis (RA). In a comparative study, tofacitinib was as effective as adalimumab. Further, tofacitinib reduced structural damages in RA and is considered as an alternative, in case of non-response, to anti-TNF and probably to other biologics therapy. The side effects are upper respiratory tract and opportunist infections and tuberculosis. Blood count, lipids, kidney function, liver tests, CK and blood pressure have to be monitored.
Antirheumatic Agents/adverse effects, Antirheumatic Agents/pharmacology, Arthritis, Rheumatoid/drug therapy, Arthritis, Rheumatoid/enzymology, Chronic Disease, Drug Approval, Humans, Inflammation/drug therapy, Inflammation/enzymology, Janus Kinases/antagonists & inhibitors, Piperidines/adverse effects, Piperidines/pharmacology, Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/pharmacology, Pyrimidines/adverse effects, Pyrimidines/pharmacology, Pyrroles/adverse effects, Pyrroles/pharmacology, Rheumatic Diseases/drug therapy, Rheumatic Diseases/enzymology, hic" UI="D013557">Switzerland
Last modification date